FrancophonIA/ELRC3.0 huggingface dataset:
English: Dexdor must not be used in patients with advanced heart block (a type of heart rhythm disorder), patients with uncontrolled low blood pressure and in patients with conditions such as stroke that affect the blood supply to the brain.
Slovenian: Zdravilo Dexdor se ne sme uporabljati pri bolnikih z napredovalim srčnim blokom (vrsto motnje srčnega ritma), pri bolnikih z nenadzorovanim nizkim krvnim tlakom in bolnikih z boleznimi, kot je možganska kap, ki prizadenejo oskrbo možganov s krvjo.
English: For more information about using Dexdor, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Dexdor glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Dexdor was compared with placebo (a dummy treatment) in two main studies involving 431 patients.
Slovenian: Zdravilo Dexdor so primerjali s placebom (zdravilom brez učinkovine) v dveh glavnih študijah, ki sta vključevali 431 bolnikov.
English: Side effects reported with Dexdor are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Dexdor, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: It is effective for awake sedation during procedures but sometimes an additional sedative medicine as well as Dexdor may be needed.
Slovenian: Učinkovito je za sedacijo v budnem stanju med posegi, vendar je včasih poleg zdravila Dexdor morda potrebno dodatno sedativno zdravilo.
English: Dexdor is a medicine used to sedate (calm or make sleepy) adult patients in the following settings:
Slovenian: Zdravilo Dexdor se uporablja za doseganje sedacije (stanja umirjenosti ali zaspanosti) odraslih bolnikov v naslednjih primerih:
English: What is Dexdor and what is it used for?
Slovenian: Kaj je zdravilo Dexdor in za kaj se uporablja?
English: What are the risks associated with Dexdor?
Slovenian: Kakšna tveganja so povezana z zdravilom Dexdor?
English: The studies in intensive care showed that Dexdor compared well with other sedatives.
Slovenian: Študije pri intenzivni negi so pokazale dobro primerljivost zdravila Dexdor z drugimi sedativi.
English: The second study involved patients undergoing a fibreoptic intubation (inserting a breathing tube through the nose or the mouth into the windpipe) while patients are awake.
Slovenian: Druga študija je vključevala bolnike, ki so prestali fiberoptično intubacijo (vstavitev dihalne cevke skozi nos ali usta v sapnik) v budnem stanju.
English: Dexdor is an additional alternative medicine for achieving lighter levels of sedation in suitable patients.
Slovenian: Zdravilo Dexdor je dodatno alternativno zdravilo za doseganje blage stopnje sedacije pri primernih bolnikih.
English: The most common side effects with Dexdor (which may affect more than 1 in 10 people) when it is used in intensive care are low or high blood pressure and bradycardia (slow heart rate).
Slovenian: Najpogostejši neželeni učinki zdravila Dexdor (ki se lahko pojavijo pri več kot 1 bolniku od 10) pri njegovi uporabi v intenzivni negi so nizek ali visok krvni tlak in bradikardija (počasen srčni utrip).
English: The patient's blood pressure, heart rate, breathing and oxygen levels should be monitored closely during the procedure.
Slovenian: Med posegom je treba skrbno spremljati bolnikov krvni tlak, srčni utrip, dihanje in ravni kisika.
English: The most common side effects when it is used for awake sedation are low blood pressure, respiratory depression (reduced ability to breathe) and bradycardia.
Slovenian: Najpogostejši neželeni učinki pri uporabi zdravila za sedacijo v budnem stanju so nizek krvni tlak, depresija dihanja (zmanjšana zmogljivost dihanja) in bradikardija.
English: A higher proportion of patients treated with Dexdor did not require additional treatment with midazolam (another sedative medicine) to maintain the desired sedation level.
Slovenian: Večji delež bolnikov, zdravljenih z zdravilom Dexdor, za ohranjanje želene stopnje sedacije ni potreboval dodatnega zdravljenja z midazolamom (drugim sedativnim zdravilom).
English: When Dexdor is used for awake sedation in diagnostic or surgical procedures, the starting dose depends on the type of procedure and the dose is adjusted to achieve the desired effect.
Slovenian: Kadar se zdravilo Dexdor uporablja za sedacijo v budnem stanju pri diagnostičnih ali kirurških posegih, je začetni odmerek odvisen od vrste posega, odmerek pa se prilagodi tako, da se doseže želeni učinek.
English: Dexdor can only be obtained with a prescription and should be given by a healthcare professional skilled in managing patients in intensive care or giving anaesthetic during diagnostic or surgical procedures.
Slovenian: Predpisovanje in izdaja zdravila Dexdor je le na recept, zdravilo pa smejo uporabljati le zdravstveni delavci, ki so izurjeni za zdravljenje bolnikov na intenzivni negi ali dajanje anestetikov med diagnostičnimi ali kirurškimi posegi.
English: When Dexdor is used in intensive care, the dose is adjusted to achieve the desired level of sedation.
Slovenian: Kadar se zdravilo Dexdor uporablja v intenzivni negi, se odmerek prilagodi tako, da se doseže želena stopnja sedacije.
English: Dexdor is given by infusion (drip) into a vein using a controlled infusion device.
Slovenian: Zdravilo Dexdor se daje z infundiranjem (kapalno infuzijo) v veno s pripomočkom za nadzorovano infundiranje.
English: For the full list of side effects and restrictions with Dexdor, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Dexdor glejte navodilo za uporabo.
English: Midazolam treatment was not required in 40% of patients receiving the lower dose of Dexdor and 54% of those receiving the higher dose compared with 3% of patients receiving placebo.
Slovenian: Zdravljenje z midazolamom ni bilo potrebno pri 40 % bolnikov, ki so prejemali manjši odmerek zdravila Dexdor, in pri 54 % bolnikov, ki so prejemali večji odmerek, v primerjavi s 3 % bolnikov, ki so prejemali placebo.
English: By reducing the activity of the sympathetic nervous system, dexmedetomidine helps to make patients calm or sleepy.
Slovenian: Deksmedetomidin z zmanjševanjem delovanja simpatičnega živčnega sistema vpliva na doseganje umirjenosti ali zaspanosti pri bolnikih.
English: Midazolam treatment was not required in 53% of patients receiving Dexdor compared with 14% receiving placebo.
Slovenian: Zdravljenje z midazolamom ni bilo potrebno pri 53 % bolnikov, ki so prejemali zdravilo Dexdor, in pri 14 % bolnikov, ki so prejemali placebo.
English: How does Dexdor work?
Slovenian: Kako zdravilo Dexdor deluje?
English: How is Dexdor used?
Slovenian: Kako se zdravilo Dexdor uporablja?
English: In the second study, 61% of patients given Dexdor maintained the required level of sedation compared with 57% of those receiving midazolam.
Slovenian: V drugi študiji je želeno stopnjo sedacije ohranilo 61 % bolnikov, ki so prejeli zdravilo Dexdor, in 57 % tistih, ki so prejeli midazolam.
English: Dexdor contains the active substance dexmedetomidine.
Slovenian: Zdravilo Dexdor vsebuje učinkovino deksmedetomidin.
English: In the first study, 65% of patients given Dexdor maintained the required level of sedation compared with 65% of those receiving propofol.
Slovenian: V prvi študiji je želeno stopnjo sedacije ohranilo 65 % bolnikov, ki so prejeli zdravilo Dexdor, in 65 % tistih, ki so prejeli propofol.
English: Care should be taken when using Dexdor in patients with reduced liver function and the dose may be reduced.
Slovenian: Kadar se zdravilo Dexdor uporablja pri bolnikih z zmanjšanim delovanjem jeter, je potrebna previdnost, odmerek pa se lahko prilagodi.
English: Dexdor was compared with other sedative medicines (propofol or midazolam) in two main studies involving 1,000 patients who required sedation in intensive care units.
Slovenian: Zdravilo Dexdor so v dveh glavnih študijah, v katerih je sodelovalo 1 000 bolnikov na oddelkih za intenzivno nego, ki so potrebovali sedacijo, primerjali z drugimi sedativnimi zdravili (propofolom ali midazolamom).
English: In 11 out of 12 patients, symptoms, including those affecting vision and movement, improved or did not get worse.
Slovenian: Pri 11 od 12 bolnikov so se simptomi, vključno s prizadetim vidom ali gibanjem, izboljšali ali se niso poslabšali.
English: The recommended dose for each infusion is 4 mg per kilogram of body weight.
Slovenian: Priporočeni odmerek pri posameznem infundiranju je 4 mg na kilogram telesne mase.
English: Treatment should also be supervised by a healthcare professional with experience in the treatment of MPS VII.
Slovenian: Zdravljenje mora tudi nadzorovati zdravstveni delavec z izkušnjami v zdravljenju MPS VII.
English: Mepsevii (vestronidase alfa)
Slovenian: Mepsevii (vestronidaza alfa)
English: Before the infusion the patient is given antihistamine treatment to reduce the risk of allergic reactions.
Slovenian: Pred infundiranjem bolnik prejme antihistaminsko zdravilo, ki zmanjša tveganje za alergijske reakcije.
English: What measures are being taken to ensure the safe and effective use of Mepsevii?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Mepsevii?
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
Slovenian: Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
English: The medicine can only be obtained with a prescription and should be given by an appropriately trained healthcare professional who can manage medical emergencies.
Slovenian: Predpisovanje in izdaja zdravila je le na recept, dajati pa ga mora ustrezno usposobljeni zdravstveni delavec, ki zna obvladovati nujne zdravstvene primere.
English: As for all medicines, data on the use of Mepsevii are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Mepsevii stalno spremljajo.
English: Since Mepsevii has been authorised under exceptional circumstances, the company that markets Mepsevii will conduct a study to provide data on the long-term effectiveness and safety of Mepsevii as well as on the disease itself, including its progression and development of symptoms.
Slovenian: Ker je zdravilo Mepsevii pridobilo dovoljenje za promet v izjemnih okoliščinah, bo podjetje, ki ga trži, izvedlo študijo, s katero bodo pridobili podatke o dolgoročni učinkovitosti in varnosti zdravila Mepsevii ter o sami bolezni, vključno z njenim napredovanjem in razvojem simptomov.
English: Side effects reported with Mepsevii are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Mepsevii, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Mepsevii is given every two weeks as an infusion (drip) into a vein lasting 4 hours.
Slovenian: Zdravilo Mepsevii se daje vsaka dva tedna kot (kapalna) infuzija v veno, ki traja štiri ure.
English: Further information on Mepsevii can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Mepsevii so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In addition, most adverse reactions are mild to moderate in severity.
Slovenian: Poleg tega je večina neželenih učinkov blagih do zmernih.
English: An overview of Mepsevii and why it is authorised in the EU
Slovenian: Pregled zdravila Mepsevii in zakaj je odobreno v EU
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mepsevii have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Mepsevii upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Mepsevii has been authorised under ‘exceptional circumstances'.
Slovenian: Zdravilo Mepsevii je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
English: Mepsevii must not be used in patients who have ever had anaphylactic reaction to vestronidase alfa or any of the other ingredients of the medicine.
Slovenian: Zdravila Mepsevii ne smejo uporabljati bolniki, ki so kadar koli imeli anafilaktično reakcijo na vestronidazo alfa ali katero koli drugo sestavino zdravila.
English: Other information about Mepsevii
Slovenian: Druge informacije o zdravilu Mepsevii
English: In a main study of 12 patients with MPS VII, patients treated with Mepsevii for 6 months had a 65% reduction in their urine levels of GAGs.
Slovenian: V glavni študiji pri 12 bolnikih z MPS VII se je raven glikozaminoglikanov v urinu pri bolnikih, ki so se šest mesecev zdravili z zdravilom Mepsevii, znižala za 65 %.
English: MPS VII is rare, and Mepsevii was designated an ‘orphan medicine' (a medicine used in rare diseases) on 21 March 2012.
Slovenian: Bolezen MPS VII je redka, zato je bilo zdravilo Mepsevii 21. marca 2012 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Why is Mepsevii authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Mepsevii odobreno v EU?
English: For more information about using Mepsevii, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Mepsevii glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: What benefits of Mepsevii have been shown in studies?
Slovenian: Kakšne koristi zdravila Mepsevii so se pokazale v študijah?
English: What is Mepsevii and what is it used for?
Slovenian: Kaj je zdravilo Mepsevii in za kaj se uporablja?
English: Mepsevii is a medicine to treat mucopolysaccharidosis type VII (MPS VII, also known as Sly syndrome), an inherited disease caused by a lack of an enzyme needed to break down complex carbohydrates known as glycosaminoglycans (GAGs).
Slovenian: Mepsevii je zdravilo za zdravljenje mukopolisaharidoze tipa VII (MPS VII, znane tudi kot Slyev sindrom), dedne bolezni, ki jo povzroča pomanjkanje encima, potrebnega za razgradnjo kompleksnih ogljikovih hidratov, imenovanih glikozaminoglikani.
English: The disease leads to build up of GAGs in the body, which causes a wide range of problems, including joint stiffness, short stature, enlarged liver and spleen, hearing loss, cataract and delays in development.
Slovenian: Pri bolezni prihaja do kopičenja glikozaminoglikanov v telesu, kar povzroča številne težave, vključno s togostjo sklepov, nizko rastjo, povečanimi jetri in vranico, izgubo sluha, sivo mreno in zapoznelim razvojem.
English: The most common side effects with Mepsevii (which may affect more than 1 in 10 people) are anaphylactic reaction (sudden, severe allergic reaction), urticaria (itchy rash) and swelling at the infusion site.
Slovenian: Najpogostejši neželeni učinki zdravila Mepsevii (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so anafilaktična reakcija (nenadna, huda alergijska reakcija), urtikarija (srbeč izpuščaj) in otekanje na mestu infundiranja.
English: What are the risks associated with Mepsevii?
Slovenian: Kakšna tveganja so povezana z zdravilom Mepsevii?
English: Mepsevii reduces the levels of GAGs in the body and improves or at least stabilises the symptoms of MPS VII.
Slovenian: Zdravilo Mepsevii znižuje ravni glikozaminoglikanov v telesu in izboljša ali vsaj stabilizira simptome MPS VII.
English: Mepsevii contains the active substance vestronidase alfa.
Slovenian: Zdravilo Mepsevii vsebuje učinkovino vestronidaza alfa.
English: What information is still awaited for Mepsevii?
Slovenian: Katere informacije o zdravilu Mepsevii še pričakujemo?
English: This is because it has not been possible to obtain complete information about Mepsevii due to the rarity of the disease and for scientific reasons.
Slovenian: To pomeni, da zaradi redkosti bolezni in iz znanstvenih razlogov ni bilo mogoče pridobiti vseh podatkov o zdravilu Mepsevii.
English: Mepsevii has been shown to reduce the levels of GAGs in the body and reduce or stabilise symptoms in patients with MPS VII.
Slovenian: Dokazali so, da zdravilo Mepsevii znižuje ravni glikozaminoglikanov v telesu in zmanjšuje ali stabilizira simptome pri bolnikih z MPS VII.
English: Mepsevii is an enzyme replacement therapy that works by replacing the missing enzyme (betaglucuronidase) in patients with MPS VII, helping to break down GAGs and stopping them building up in the body.
Slovenian: Mepsevii je zdravilo za nadomestno encimsko zdravljenje, ki pri bolnikih z MPS VII nadomešča manjkajoči encim (beta-glukuronidazo) in jim pomaga razgraditi glikozaminoglikane ter ustavi njihovo kopičenje v telesu.
English: Although only a limited amount of data is available from clinical studies, the European Medicines Agency took into account the life-threatening and debilitating nature of MPS VII and the lack of authorised medicines.
Slovenian: Čeprav so iz kliničnih študij na voljo le omejeni podatki, je Evropska agencija za zdravila upoštevala, da je MPS VII smrtno nevarna in izčrpavajoča bolezen ter da odobrenih zdravil ni. Agencija EMA je zaključila, da so koristi zdravila Mepsevii večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: How is Mepsevii used?
Slovenian: Kako se zdravilo Mepsevii uporablja?
English: How does Mepsevii work?
Slovenian: Kako zdravilo Mepsevii deluje?
English: This overview was last updated in 08-2018.
Slovenian: Če bo potrebno, bo posodobljen tudi ta povzetek.
English: Invented name Strength Pharmaceutical form
Slovenian: (Izmišljeno) ime Jakost Farmacevtska oblika
English: 120 filmcoated tablets
Slovenian: 120 filmsko obloženih tablet
English: 500 mg Film-Coated tablet
Slovenian: 500 mg Filmsko obložena tableta
English: Oral use bottle (HDPE)
Slovenian: Steklenička (HDPE)
English: Please note the following:
Slovenian: Prosimo, upoštevajte naslednje:
English: No specific recommendation.
Slovenian: Ni posebnega priporočila.
English: However, try to take your tablet at the same time every day.
Slovenian: Vendar skušajte tableto vzeti vsak dan ob istem času.
English: Absolute Risk Reduction1
Slovenian: absolutno zmanjšanje tveganja1
English: The mechanism of this interaction is not known.
Slovenian: Mehanizem tega medsebojnega delovanja ni znan.
English: Possible consequences for the efficacy are unknown.
Slovenian: Možne posledice na učinkovitost so neznane.
English: Median follow-up was 4.9 years.
Slovenian: Mediano spremljanje je trajalo 4,9 leta.
English: You should consult your doctor as soon as possible.
Slovenian: Posvetujte se z zdravnikom takoj, ko bo mogoče.
English: • ringing in the ears and/or head
Slovenian: • zvonjenje v ušesih in/ali v glavi,
English: This type of interaction could make one or both of the medicines less effective.
Slovenian: Takšno medsebojno delovanje lahko zmanjša učinkovitost enega ali obeh zdravil.
English: After the Commission decision the Member State competent authorities, in liaison with the reference Member State, will update the product information as required.
Slovenian: Po odločbi Komisije bodo pristojni organi v državah članicah skupaj z referenčno državo članico v skladu z zahtevami posodobili podatke o zdravilu.
English: ↓ 35%^ No specific recommendation.
Slovenian: 35 % ↓^ Ni posebnega priporočila.
English: Change in AUC&
Slovenian: Sprememba AUC&
English: Increase is indicated as “↑”, decrease as “↓”
Slovenian: Povečanje je prikazano kot “↑”, zmanjšanje kot “↓”
English: This medicinal product is authorised in the Member States of the EEA under the following names: Austria, Bulgaria, Czech Republic, Estonia,
Slovenian: Zdravilo je v državah članicah EGP pridobilo dovoljenje za promet z naslednjimi imeni: Avstrija, Bolgarija, Češka, Estonija, Nemčija,
English: These changes were usually mild, transient, and did not require interruption of treatment.
Slovenian: Te spremembe so ponavadi blage in prehodne ter zdravljenja zaradi njih ni treba prekiniti.
English: Only limited data are available (see section 5.1).
Slovenian: Na voljo je le malo podatkov (glejte poglavje 5.1).
English: The absolute and relative risk reduction effect of atorvastatin was as follows:
Slovenian: Učinek atorvastatina na absolutno in relativno zmanjšanje tveganja je bil naslednji:
English: • allergic reactions
Slovenian: • alergijske reakcije,
English: Clinical Recommendation#
Slovenian: Klinično priporočilo#
English: Use in the elderly
Slovenian: Uporaba pri starejših
English: Therefore, the clinical significance of these imaging results with regard to the primary and secondary prevention of cardiovascular events is unknown.
Slovenian: Zato je klinični pomen rezultatov teh preiskav glede na primarno in sekundarno preprečevanje srčnožilnih dogodkov neznan.
English: Before the treatment
Slovenian: Pred zdravljenjem
English: Prevention of cardiovascular disease
Slovenian: Preprečevanje srčnožilnih bolezni
English: Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of {PRODUCT NAME}.
Slovenian: Na dan ne spijte več kot en ali dva majhna kozarca grenivkinega soka, saj lahko le-ta v velikih količinah spremeni učinek zdravila {(Lastniško) ime}.
English: These elevations were dose related and were reversible in all patients.
Slovenian: Zvišanje je bilo povezano z velikostjo odmerka in je bilo pri vseh bolnikih reverzibilno.
English: For these reasons, {PRODUCT NAME} should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant.
Slovenian: Zaradi teh razlogov se zdravilo {(Lastniško) ime} ne sme uporabljati pri nosečnicah, ženskah, ki poskušajo zanositi ali sumijo, da so noseče.
English: Gemfibrozil / fibric acid derivatives
Slovenian: Gemfibrozil / derivati fibrinske kisline
English: • Sexual dysfunction.
Slovenian: • spolna disfunkcija,
English: There are some medicines that may change the effect of {PRODUCT NAME} or their effect may be changed by {PRODUCT NAME}.
Slovenian: Nekatera zdravila lahko spremenijo učinek zdravila {(Lastniško) ime}ali pa zdravilo {(Lastniško) ime} vpliva na njihov učinek.
English: If you forget to take a dose, just take your next scheduled dose at the correct time.
Slovenian: Če pozabite vzeti odmerek, vzemite naslednji odmerek ob predpisanem času.
English: Important information about some of the ingredients of {PRODUCT NAME} If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Slovenian: Pomembne informacije o nekaterih sestavinah zdravila {(Lastniško) ime} Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
English: Possible side effects reported with some statins (medicines of the same type):
Slovenian: Možni neželeni učinki, opisanimi z nekaterimi statini (zdravili iste vrste):
English: 38 vs 64
Slovenian: 38 v primerjavi s 64
English: If you are at an increased risk of heart disease, {PRODUCT NAME} can also be used to reduce such risk even if your cholesterol levels are normal.
Slovenian: Če imate povišano tveganje za srčne bolezni, se lahko zdravilo {(Lastniško) ime} uporablja tudi za zmanjševanje takšnega tveganja, čeprav je raven holesterola v vaši krvi normalna.
English: Extent of absorption increases in proportion to atorvastatin dose.
Slovenian: Delež absorpcije se povečuje sorazmerno z odmerkom atorvastatina.
English: Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations (Cmax) occur within 1 to 2 hours.
Slovenian: Atorvastatin se po peroralni uporabi hitro absorbira; največjo koncentracijo v plazmi (Cmax) doseže v 1 do 2 urah.
English: From these 89 patients, the mean percent reduction in LDL-C was approximately 20%.
Slovenian: Pri teh 89 bolnikih je bilo povprečno zmanjšanje LDL-H za 20 %.
English: CYP3A4 inducers
Slovenian: CYP3A4 induktorji